| Oct 16 |
Bright Minds rally ends as psychedelic stocks extend volatility
|
| Oct 16 |
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views
|
| Oct 16 |
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
|
| Oct 16 |
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
|
| Oct 16 |
Biotech stock tumbles after unexplained 1,446% gain
|
| Oct 16 |
Bright Minds is Unaware of Any Material Changes
|
| Oct 3 |
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
|
| Sep 19 |
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
|
| Sep 12 |
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
|
| Aug 31 |
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
|
